Exploring the perspectives of stakeholders for homologous recombination deficient (HRD) biomarker testing to guide precision medicine for advanced ovarian cancer treatment
HRD testing is an effective biomarker test for the treatment management for advanced ovarian cancer. Currently, HRD testing is not funded publicly for all individuals in Canada.
Leads
Helen McTaggart-Cowan